2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Omics Technologies, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Immune Mechanism, Microbiome, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Diseases, Hemoglobinopathies, Thalassemia, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Bacterial, Fungal, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Clinical Trials, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Young Adult, Animal Model
PAPER

4232 Torque teno virus species profiles and prognostic value early after allo-HSCT: A metagenomic next-generation sequencing based retrospective study

Xiujuan Ma, MS, Xintong Han, N/A2, Fang Wang, MD3, Jing Long4, Xiaosu Zhou, PhD5, Hongxing Liu, MD6
1 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
2 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
3 Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China
4 Beijing Lu Daopei Hospital, Beijing, China
5 Beijing Lu Daopei Institute of Hematology, Beijing, China
6 Beijing Lu Daopei Hospital, Beijing, China, Beijing Lu Daopei Institute of Hematology, Beijing, China, Hebei Yanda Lu Daopei Hospital, Langfang, Hebei, China

Background: Torque teno virus (TTV; genus Alphatorquevirus), a ubiquitous human commensal virus whose replication mirrors host immune status, is an established "sentinel virus" for immune monitoring in solid organ transplantation. Its clinical utility is increasingly being explored in allogeneic hematopoietic stem cell transplantation (allo-HSCT), where TTV dynamics have been linked to immune reconstitution and post-transplant outcomes; however, the epidemiological profile of TTV species and their associations with graft-versus-host disease (GVHD), infections, and survival remain controversial and incompletely defined.

Objective: To characterize the plasma TTV species profile in patients undergoing allo-HSCT and evaluate its associations with GVHD, infection risks, and clinical outcomes.

Methods: A retrospective analysis was performed on 732 allo-HSCT recipients who underwent metagenomic next-generation sequencing (mNGS) during hospitalization at Hebei Yanda Lu Daopei Hospital between January 2021 and December 2023. Patients were stratified by mNGS testing timing into pre-transplant (n=255) and post-transplant (n=477) groups, and further by TTV detection into pre-transplant TTV-positive (n=66) vs. negative (n=189) and post-transplant TTV-positive (n=207) vs. negative (n=270) subgroups. Clinical characteristics and infectious events were compared using Pearson's χ² test. Overall survival (OS) was assessed by Kaplan-Meier analysis and multivariable Cox proportional hazards models to identify risk factors.

Results: Baseline age and sex were well-balanced between the pre-transplant group (148 males [58.0%], median age 26 years [IQR:12–41]) and the post-transplant group (278 males [58.3%], median age 27 years [IQR:13–38]). TTV positivity was significantly higher post- than pre-transplantation (P=3.0E-6); despite TTV-24 remaining predominant at both time points, TTV-29 increased markedly after transplantation (30.4% vs. 7.6% pre-transplantation, P=1.9E-4).

Further analysis revealed that among the 70 post-transplant patients with events or censoring within 5 months post-transplantation (32 TTV-positive [45.7%] and 38 TTV-negative [54.3%]), TTV positivity was associated with faster hematopoietic recovery (higher neutrophil and platelet engraftment [≤28 days: 100% vs. 76.3%, P=0.003 and 90.0% vs. 40.7%, P=1.0E-4, respectively]) and lower bacterial infection rates (34.4% vs. 63.2%, P=0.016). Although acute GVHD (aGVHD) incidence was higher in the TTV-positive group (71.9% vs. 36.8%, P=0.003), multivariable Cox regression identified delayed neutrophil engraftment (>28 days) as the sole independent risk factor for mortality at this early stage HR=4.458, 95% CI: 1.576–12.612, P=0.005).

Stratifying the post-transplant cohort (n=477) by mNGS testing timing (≤5 months, n = 336; >5 months, n = 141), TTV positivity in the ≤5-month subgroup was associated with significantly inferior 3-year OS than TTV negativity (61.7% vs. 77.6%, P = 0.011; median follow-up, 27.9 months), whereas TTV status in the >5-month subgroup showed no significant association (P = 0.889). In the ≤5-month subgroup, baseline characteristics (age, sex, underlying disease, and donor type) were comparable between the TTV-positive and TTV-negative groups (all P>0.05). However, TTV-positive patients exhibited significantly higher rates of rapid neutrophil engraftment (≤28 days; 99.3% vs. 94.9%), aGVHD (64.5% vs. 47.7%), and chronic GVHD (36.2% vs. 22.6%) (all P<0.05), along with lower rates of bacterial and fungal infections (all P<0.05). Multivariable Cox regression confirmed TTV positivity within 5 months, delayed neutrophil engraftment (>28 days), and bacterial/fungal infections as independent risk factors for overall mortality.

Conclusions:

TTV positivity is highly prevalent post-allo-HSCT, with reshaped species composition marked by increased TTV-29, suggesting that transplant-related immune reconstitution drives host TTV population dynamics. Delayed neutrophil engraftment (>28 days) is the main independent risk factor for early mortality (≤5 months), highlighting early hematopoietic recovery as a determinant of short-term prognosis. TTV positivity within 5 months post-transplantation is an independent early warning signal for immune dysregulation and poor long-term outcomes: despite accelerated engraftment and reduced bacterial infection risk, it heralds higher GVHD incidence and reduced long-term survival; no prognostic value was observed beyond 5 months.
Xiujuan Ma, MS: No relevant conflicts of interest to declare.